Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
27 févr. 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
16 janv. 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive...
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
10 janv. 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777...
Aclaris Therapeutics Provides Corporate Update
19 déc. 2023 16h01 HE
|
Aclaris Therapeutics, Inc.
- ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19,...
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
05 déc. 2023 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory...
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
13 nov. 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and...
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
06 nov. 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced;...
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
03 oct. 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
20 sept. 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
18 sept. 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc....